Siwen Hu-Lieskovan, MD, PhD
Dr. Siwen Hu-Lieskovan, MD (China Medical University), Ph.D. (University of Southern California), Residency (USC Medical Center), Hem/Onc fellowship (UCLA School of Medicine), assistant professor of medicine at the UCLA David Geffen School of Medicine. Selected honor and leadership roles: member of the NCI CTEP (Cancer Therapy and Evaluation Program) TVEC Project Team, study chair and translational lead of several SWOG immunotherapy trials against melanoma, ASCO Young Investigator Award and Career Development Award, ASCO Annual Meeting Merit Award, AACR Astra Zeneca Scholar In Training Award, AACR/ASCO MCCR Dan Von Hoff Best Protocol Development Award, Tower Cancer Research Foundation Grant. Area of focus: Melanoma, cancer immunotherapy (tumor immune microenvironment, biomarkers, combination strategies) and translational research.
Wei Ding, MD, PhD
Wei Ding, MD (Beijing Medical University), Ph.D. (Ohio State University), Residency and Hem/Onc fellowship (Mayo Clinic), associate professor of medicine and oncology at Mayo Clinic. Selected honors and leadership roles: member of NCI-CTEP, national PI for multiple trials, NCI-K23 awardee and LLS co-investigator. Area of focus: CLL and other hematological malignancies (Bone marrow environment, immunotherapy and PI3K/AKT pathway).